Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells

Biochemical Pharmacology

Volumn 67, Issue 8, 2004, Pages 1469-1478

  Maier, Thorsten Jürgen ^a   Schilling, Karin ^a   Schmidt, Ronald ^a   Geisslinger, Gerd ^a   Grösch, Sabine ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

COX 2; Cyclooxygenase 2; EIA; Enzyme linked immunoassay; FCS; Fetal calf serum; Non steroidal anti inflammatory drug; NSAID; PARP; PGE2; Poly(ADP) ribose polymerase; Prostaglandin E 2; Reverse transcription polymerase chain reaction; RT PCR

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 9; CELECOXIB; COMPLEMENTARY DNA; CYCLIN A; CYCLIN B1; CYCLOOXYGENASE 2; CYTOCHROME C; PROTEIN P21; PROTEIN P27;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL STRAIN CACO 2; CELL SURVIVAL; COLON CARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; ENZYME ACTIVATION; ENZYME RELEASE; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOLECULAR CLONING; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTICARCINOGENIC AGENTS; APOPTOSIS; CACO-2 CELLS; CELL CYCLE; CELL CYCLE PROTEINS; CELL SURVIVAL; COLONIC NEOPLASMS; CYCLIN A; CYCLIN B; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLINS; CYCLOOXYGENASE 2; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; SULFONAMIDES; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 1642407595     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2003.12.014     Document Type: Article

References (38)

1. Fosslien E. Molecular pathology of cyclooxygenase-2 in neoplasia. Ann. Clin. Lab. Sci. 30(1):2000;3-21.
2. Giardiello F.M., Spannhake E.W., DuBois R.N., Hylind L.M., Robinson C.R., Hubbard W.C., Hamilton S.R., Yang V.W. Prostaglandin levels in human colorectal mucosa: effects of sulindac in patients with familial adenomatous polyposis. Dig. Dis. Sci. 43(2):1998;311-316.
3. Steinbach G., Lynch P.M., Phillips R.K., Wallace M.H., Hawk E., Gordon G.B., Wakabayashi N., Saunders B., Shen Y., Fujimura T., Su L.K., Levin B. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. New Engl. J. Med. 342(26):2000;1946-1952.
4. Sano H., Kawahito Y., Wilder R.L., Hashiramoto A., Mukai S., Asai K., Kimura S., Kato H., Kondo M., Hla T. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res. 55(17):1995;3785-3789.
5. Eberhart C.E., Coffey R.J., Radhika A., Giardiello F.M., Ferrenbach S., DuBois R.N. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 107:1994;1183-1188.
6. Liu X.H., Kirschenbaum A., Yao S., Stearns M.E., Holland J.F., Claffey K., Levine A.C. Upregulation of vascular endothelial growth factor by cobalt chloride-simulated hypoxia is mediated by persistent induction of cyclooxygenase-2 in a metastatic human prostate cancer cell line. Clin. Exp. Metastasis. 17(8):1999;687-694.
7. Sheng H., Shao J., Morrow J.D., Beauchamp R.D., DuBois R.N. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res. 58(2):1998;362-366.
8. Tsujii M., DuBois R.N. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell. 83(3):1995;493-501.
9. Subbaramaiah K., Dannenberg A.J. Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol. Sci. 24(2):2003;96-102.
10. Zweifel B.S., Davis T.W., Ornberg R.L., Masferrer J.L. Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E(2) in human head and neck xenograft tumors. Cancer Res. 62(22):2002;6706-6711.
11. Reddy B.S., Hirose Y., Lubet R., Steele V., Kelloff G., Paulson S., Seibert K., Rao C.V. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res. 60(2):2000;293-297.
12. Grosch S., Tegeder I., Niederberger E., Brautigam L., Geisslinger G. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J. 15(14):2001;2742- 2744.
13. Tegeder I., Pfeilschifter J., Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J. 15(12):2001;2057-2072.
14. Yamazaki R., Kusunoki N., Matsuzaki T., Hashimoto S., Kawai S. Selective cyclooxygenase-2 inhibitors show a differential ability to inhibit proliferation and induce apoptosis of colon adenocarcinoma cells. FEBS Lett. 531(2):2002;278-284.
15. McCracken J.D., Wechter W.J., Liu Y., Chase R.L., Kantoci D., Murray E.D. Jr., Quiggle D.D., Mineyama Y. Antiproliferative effects of the enantiomers of flurbiprofen. J. Clin. Pharmacol. 36(6):1996;540-545.
16. Wechter W.J., Kantoci D., Murray E.D. Jr., Quiggle D.D., Leipold D.D., Gibson K.M., McCracken J.D. R-flurbiprofen chemoprevention and treatment of intestinal adenomas in the APC(Min)/+ mouse model: implications for prophylaxis and treatment of colon cancer. Cancer Res. 57(19):1997;4316-4324.
17. Reddy B.S., Kawamori T., Lubet R.A., Steele V.E., Kelloff G.J., Rao C.V. Chemopreventive efficacy of sulindac sulfone against colon cancer depends on time of administration during carcinogenic process. Cancer Res. 59(14):1999;3387-3391.
18. Stoner G.D., Budd G.T., Ganapathi R., DeYoung B., Kresty L.A., Nitert M., Fryer B., Church J.M., Provencher K., Pamukcu R., Piazza G., Hawk E., Kelloff G., Elson P., van Stolk R.U. Sulindac sulfone induced regression of rectal polyps in patients with familial adenomatous polyposis. Adv. Exp. Med. Biol. 470:1999;45-53.
19. Song X., Lin H.P., Johnson A.J., Tseng P.H., Yang Y.T., Kulp S.K., Chen C.S. Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. J. Natl. Cancer Inst. 94(8):2002;585-591.
20. Bräutigam L., Vetter G., Tegeder I., Heinkele G., Geisslinger G. Determination of Celecoxib in human plasma and rat microdialysis samples by liquid chromatography tandem mass spectrometry. J. Chromatogr. Biomed. Appl. 261(2):2001;203-212.
21. Li M., Wu X., Xu X.C. Induction of apoptosis by cyclo-oxygenase-2 inhibitor NS398 through a cytochrome c-dependent pathway in esophageal cancer cells. Int. J. Cancer. 93(2):2001;218-223.
22. Li M., Wu X., Xu X.C. Induction of apoptosis in colon cancer cells by cyclooxygenase-2 inhibitor NS398 through a cytochrome c-dependent pathway. Clin. Cancer Res. 7(4):2001;1010-1016.
23. Chang H.C., Weng C.F. Cyclooxygenase-2 level and culture conditions influence NS398-induced apoptosis and caspase activation in lung cancer cells. Oncol. Rep. 8(6):2001;1321-1325.
24. Hsu A.L., Ching T.T., Wang D.S., Song X., Rangnekar V.M., Chen C.S. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J. Biol. Chem. 275(15):2000;11397-11403.
25. Houchen C.W., Sturmoski M.A., Anant S., Breyer R.M., Stenson W.F. Prosurvival and antiapoptotic effects of PGE2 in radiation injury are mediated by EP2 receptor in intestine. Am. J. Physiol. Gastrointest. Liver Physiol. 284(3):2003;G490-G498.
26. Sanchez T., Moreno J.J. Role of EP(1) and EP(4) PGE(2) subtype receptors in serum-induced 3T6 fibroblast cycle progression and proliferation. Am. J. Physiol. Cell Physiol. 282(2):2002;C280-C288.
27. Fujino T., Yuhki K., Yamada T., Hara A., Takahata O., Okada Y., Xiao C.Y., Ma H., Karibe H., Iwashima Y., Fukuzawa J., Hasebe N., Kikuchi K., Narumiya S., Ushikubi F. Effects of the prostanoids on the proliferation or hypertrophy of cultured murine aortic smooth muscle cells. Br. J. Pharmacol. 136(4):2002;530-539.
28. Hansen-Petrik M.B., McEntee M.F., Jull B., Shi H., Zemel M.B., Whelan J. Prostaglandin E(2) protects intestinal tumors from nonsteroidal anti-inflammatory drug-induced regression in Apc(Min/+) mice. Cancer Res. 62(2):2002;403-408.
29. Kawamori T., Rao C.V., Seibert K., Reddy B.S. Chemopreventive activity of Celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res. 58:1998;409-412.
30. Leng J., Han C., Demetris A.J., Michalopoulos G.K., Wu T. Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis. Hepatology. 38(3):2003;756-768.
31. Narayanan B.A., Condon M.S., Bosland M.C., Narayanan N.K., Reddy B.S. Suppression of N-methyl-N-nitrosourea/testosterone-induced rat prostate cancer growth by celecoxib: effects on cyclooxygenase-2, cell cycle regulation, and apoptosis mechanism(s). Clin. Cancer Res. 9(9):2003;3503-3513.
32. Patti R., Gumired K., Reddanna P., Sutton L.N., Phillips P.C., Reddy C.D. Overexpression of cyclooxygenase-2 (COX-2) in human primitive neuroectodermal tumors: effect of celecoxib and rofecoxib. Cancer Lett. 180(1):2002;13-21.
33. Waskewich C., Blumenthal R.D., Li H., Stein R., Goldenberg D.M., Burton J. Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Cancer Res. 62(7):2002;2029-2033.
34. Hawk E.T., Viner J.L., Dannenberg A., DuBois R.N. COX-2 in cancer - a player that's defining the rules. J. Natl. Cancer Inst. 94(8):2002;545-546.
35. 2+-ATPases: a plausible link with its anti-tumour effect and cardiovascular risks. Biochem. J. 366(Pt. 3):2002;831-837.
36. Jendrossek V., Handrick R., Belka C. Celecoxib activates a novel mitochondrial apoptosis signaling pathway. FASEB J. 17(11):2003;1547-1549.
37. Arico S., Pattingre S., Bauvy C., Gane P., Barbat A., Codogno P., Ogier-Denis E. Celecoxib induces apoptosis by inhibiting 3-phosphoinositide- dependent protein kinase-1 activity in the human colon cancer HT-29 cell line. J. Biol. Chem. 277(31):2002;27613-27621.
38. Kundu N., Smyth M.J., Samsel L., Fulton A.M. Cyclooxygenase inhibitors block cell growth. Breast Cancer Res. Treat. 76(1):2002;57-64.